Omega Therapeutics Q1 2022 Earnings Report
Key Takeaways
Omega Therapeutics reported a net loss of $20.2 million for the first quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $200.8 million as of March 31, 2022. They are on track to file an IND for OTX-2002 in the first half of 2022.
Investigational New Drug Application for OTX-2002 for MYC Driven Hepatocellular Carcinoma on Track to be Submitted in the First Half of 2022
Additional Omega Epigenomic Controllerâ„¢ Development Candidates on Track to be Nominated in the Middle of 2022
Presented New OTX-2002 Preclinical Data in Hepatocellular Carcinoma at AACR 2022 that Highlighted the Potential of OTX-2002 to Downregulate Overexpression of the MYC Oncogene in Models of HCC
Abstract on OEC for Non-Small Cell Lung Cancer Selected for Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
Omega Therapeutics
Omega Therapeutics
Forward Guidance
Omega Therapeutics is focused on advancing into the clinic this year, starting with their expected Investigational New Drug (IND) Application for OTX-2002 in the first half of 2022.